FY2025 Earnings Estimate for Neogen Issued By William Blair

Neogen Corporation (NASDAQ:NEOG - Free Report) - Stock analysts at William Blair dropped their FY2025 earnings per share estimates for Neogen in a research report issued on Wednesday, June 18th. William Blair analyst B. Vazquez now anticipates that the company will post earnings per share of $0.29 for the year, down from their previous forecast of $0.31. The consensus estimate for Neogen's current full-year earnings is $0.38 per share. William Blair also issued estimates for Neogen's Q4 2025 earnings at $0.07 EPS, FY2026 earnings at $0.24 EPS and FY2027 earnings at $0.29 EPS.

Several other equities research analysts have also recently commented on NEOG. Guggenheim cut their target price on Neogen from $15.00 to $13.00 and set a "buy" rating on the stock in a research note on Thursday, April 10th. Piper Sandler lowered their price target on Neogen from $6.40 to $5.00 and set a "neutral" rating on the stock in a research report on Tuesday, April 22nd.

Neogen Trading Down 3.4%

Shares of Neogen stock traded down $0.17 during trading on Monday, hitting $4.77. 7,010,755 shares of the company were exchanged, compared to its average volume of 3,286,907. Neogen has a 1-year low of $3.87 and a 1-year high of $18.58. The company has a debt-to-equity ratio of 0.33, a current ratio of 3.91 and a quick ratio of 2.45. The firm has a market capitalization of $1.04 billion, a P/E ratio of -2.14 and a beta of 1.84. The firm's fifty day moving average price is $5.56 and its 200 day moving average price is $8.70.

Neogen (NASDAQ:NEOG - Get Free Report) last announced its earnings results on Wednesday, April 9th. The company reported $0.10 earnings per share for the quarter, missing analysts' consensus estimates of $0.12 by ($0.02). The business had revenue of $221.00 million during the quarter, compared to analyst estimates of $225.27 million. Neogen had a negative net margin of 53.56% and a positive return on equity of 2.69%. The business's quarterly revenue was down 3.4% compared to the same quarter last year. During the same quarter last year, the business posted $0.12 earnings per share.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NEOG. Blue Trust Inc. lifted its holdings in Neogen by 247.6% during the 4th quarter. Blue Trust Inc. now owns 3,945 shares of the company's stock worth $48,000 after purchasing an additional 2,810 shares in the last quarter. Bank Pictet & Cie Europe AG raised its holdings in shares of Neogen by 6.5% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 132,000 shares of the company's stock valued at $1,602,000 after acquiring an additional 8,000 shares in the last quarter. Rhumbline Advisers raised its holdings in shares of Neogen by 0.7% in the 4th quarter. Rhumbline Advisers now owns 699,490 shares of the company's stock valued at $8,492,000 after acquiring an additional 4,890 shares in the last quarter. State of New Jersey Common Pension Fund D increased its position in shares of Neogen by 19.2% during the 4th quarter. State of New Jersey Common Pension Fund D now owns 139,110 shares of the company's stock valued at $1,689,000 after purchasing an additional 22,429 shares during the last quarter. Finally, Principal Financial Group Inc. increased its position in shares of Neogen by 1.8% during the 4th quarter. Principal Financial Group Inc. now owns 590,327 shares of the company's stock valued at $7,167,000 after purchasing an additional 10,254 shares during the last quarter. 96.73% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, Director James P. Tobin bought 10,000 shares of the company's stock in a transaction on Tuesday, April 22nd. The stock was purchased at an average cost of $4.73 per share, for a total transaction of $47,300.00. Following the completion of the transaction, the director now owns 37,474 shares of the company's stock, valued at $177,252.02. This trade represents a 36.40% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Amy M. Rocklin purchased 12,500 shares of Neogen stock in a transaction that occurred on Wednesday, April 23rd. The stock was acquired at an average cost of $4.99 per share, with a total value of $62,375.00. Following the transaction, the insider now owns 36,287 shares in the company, valued at $181,072.13. This trade represents a 52.55% increase in their position. The disclosure for this purchase can be found here. Insiders acquired a total of 83,500 shares of company stock worth $431,525 in the last ninety days. 1.13% of the stock is owned by insiders.

Neogen Company Profile

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.